Therapeutic Potential of Extracellular Vesicles for Demyelinating Diseases; Challenges and Opportunities

Multiple Sclerosis is a demyelinating disease of the central nervous system for which no remyelination therapy is available and alternative strategies are being tested. Extracellular vesicles (EVs) have emerged as players in physiological and pathological processes and are being proposed as therapeu...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in molecular neuroscience Vol. 11; p. 434
Main Authors: Osorio-Querejeta, Iñaki, Alberro, Ainhoa, Muñoz-Culla, Maider, Mäger, Imre, Otaegui, David
Format: Journal Article
Language:English
Published: Switzerland Frontiers Research Foundation 23-11-2018
Frontiers Media S.A
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple Sclerosis is a demyelinating disease of the central nervous system for which no remyelination therapy is available and alternative strategies are being tested. Extracellular vesicles (EVs) have emerged as players in physiological and pathological processes and are being proposed as therapeutic targets and mediators. More concretely, EVs have shown to be involved in myelination related processes such as axon-oligodendrocyte communication or oligodendrocyte precursor cell migration. In addition, EVs have been shown to carry genetic material and small compounds, and to be able to cross the Blood Brain Barrier. This scenario led scientists to test the ability of EVs as myelin regeneration promoters in demyelinating diseases. In this review we will address the use of EVs as remyelination promoters and the challenges and opportunities of this therapy will be discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Thierry Burnouf, Taipei Medical University, Taiwan; Pablo Villoslada, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain
Edited by: David Blum, INSERM U1172 Centre de Recherche Jean Pierre Aubert, France
ISSN:1662-5099
1662-5099
DOI:10.3389/fnmol.2018.00434